National Association of Pharmacy Regulatory Authorities
National Association of Pharmacy Regulatory Authorities

Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Reset
Print Friendly Export to CSV
Drug Name Comment Schedule Date
Rabeprazole or its saltsPDL I DEC / 13
Rabies immune globulin I FEB / 02
Rabies vaccine I FEB / 02
Racemethionine II SEP / 98
RacemethorphanN I JUN / 02
RacemoramideN I JUN / 02
RacemorphanN I JUN / 02
Raloxifene or its saltsPDL I DEC / 13
Raltegravir or its saltsPDL I DEC / 13
Raltitrexed or its salts or derivativesPDL

Including but not limited to raltitrexed disodium.

 I DEC / 13
Ramipril or its salts or derivativesPDL I DEC / 13
RamucirumabPDL I OCT / 15
RanibizumabPDL I DEC / 13
Ranitidine or its saltsPDL

For human use - except when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn.

 I DEC / 13
Ranitidine or its salts. when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 4,500 mg of ranitidine III MAR / 08
Ranitidine or its salts.. when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing no more than 4,500 mg of ranitidine U FEB / 07
Rasagiline or its saltsPDL I DEC / 13
RasburicasePDL I DEC / 13
Raubasine or its saltsPDL I DEC / 13
RauwolfiaPDL I DEC / 13
RavulizumabPDL I OCT / 19
Regorafenib or its saltsPDL I DEC / 13
Remestemcel-LPDL I DEC / 13
RemifentanilN I JUN / 02
Remoxipride or its saltsPDL I DEC / 13
Repaglinide or its salts or derivativesPDL I DEC / 13
Rescinnamine or its saltsPDL I DEC / 13
Reserpine or its saltsPDL

For human use.

 I DEC / 13
ReslizumabPDL I JUN / 17
Resocortol and its derivatives.FR AUG / 06
Resocortol or its derivativesPDL I DEC / 13
RetapamulinPDL I DEC / 13
Reviparin or its saltsPDL I DEC / 13
Rho D immune globulin I FEB / 02
RibavirinPDL I DEC / 13
Ribociclib or its saltsPDL I MAY / 18
Rifabutin or its saltsPDL I DEC / 13
Rifampin or its salts or derivativesPDL I DEC / 13
Rifaximin or its salts or derivativesPDL I DEC / 13
Rilpivirine or its salts or derivativesPDL

Including but not limited to rilpivirine hydrochloride.

 I DEC / 13
Riluzole or its saltsPDL I DEC / 13
Riociguat or its derivativesPDL I DEC / 13
RisankizumabPDL I JUL / 19
Risedronic acid or its saltsPDL I DEC / 13
Risperidone or its saltsPDL I DEC / 13
Ritodrine and its saltsPDL I DEC / 13
RitonavirPDL I DEC / 13
RituximabPDL I DEC / 13
RivaroxabanPDL I DEC / 13
Rivastigmine or its saltsPDL I DEC / 13
Rizatriptan or its saltsPDL I DEC / 13
Robenacoxib or its saltsPDL I DEC / 13
Rocuronium bromidePDL I DEC / 13
RofecoxibPDL I DEC / 13
Roflumilast or its salts or derivativesPDL I DEC / 13
RomidepsinPDL I DEC / 13
Romifidine or its saltsPDL I DEC / 13
RomiplostimPDL I DEC / 13
Romosozumab PDL I OCT / 19
Ronidazole or its salts or derivativesPDL

For human use.

 I DEC / 13
Ropinirole or its saltsPDL I DEC / 13
Rose Bengal II SEP / 98
Rosiglitazone or its saltsPDL I DEC / 13
Rosoxacin or its saltsPDL I DEC / 13
Rosuvastatin or its saltsPDL I DEC / 13
Rotigotine or its salts or derivativesPDL I DEC / 13
Rubella vaccine II DEC / 98
Rue and its preparations and extracts II SEP / 98
Rufinamide or its derivativesPDL I DEC / 13
Rupatadine or its saltsPDL I FEB / 17
Ruxolitinib or its saltsPDL

Including but not limited to ruxolitinib phosphate.

 I DEC / 13

71 result(s)

Print Friendly Export to CSV

Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled